Modest growth expected for hepatitis B vaccine market

The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from around $959.9 million in 2012 to $1.19 billion by 2022, at a compound annual growth rate (CAGR) of 2.2%.

According to a new report from research and consulting firm GlobalData, out of the eight major markets - the USA, Canada, France, Germany, Italy, Spain, the UK and Japan - the majority of HBV vaccine sales will take place in the USA, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The USA will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively.

Growth to be led by launch of Heplisav and Hexyon